Terms: = Prostate cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Diagnosis
6 results:
1. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
2. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
Gopalan A
Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
[TBL] [Abstract] [Full Text] [Related]
3. A modern era of personalized medicine in the diagnosis, prognosis, and treatment of prostate cancer.
Lakshmanan VK; Ojha S; Jung YD
Comput Biol Med; 2020 Nov; 126():104020. PubMed ID: 33039808
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract] [Full Text] [Related]
5. Inhibition of n-myc downstream-regulated gene 2 in prostatic carcinoma.
Yu C; Wu G; Dang N; Zhang W; Zhang R; Yan W; Zhao Y; Gao L; Wang Y; Beckwith N; Yuan J; Yao L
Cancer Biol Ther; 2011 Aug; 12(4):304-13. PubMed ID: 21623166
[TBL] [Abstract] [Full Text] [Related]
6. Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
Munoz M; Henderson M; Haber M; Norris M
IUBMB Life; 2007 Dec; 59(12):752-7. PubMed ID: 18085475
[TBL] [Abstract] [Full Text] [Related]
